The looksmaxxing tier list hierarchy is determined by three variables: magnitude of phenotypic change, speed of onset, and durability after cessation. S-tier interventions produce visible changes within 8-12 weeks, require minimal ongoing titration, and address multiple aesthetic vectors simultaneously. A-tier protocols demand higher technical precision or produce narrower effects. B-tier and below offer marginal gains relative to cost, risk, or time investment. This ranking reflects observed outcomes across hundreds of n=1 experiments, not theoretical mechanisms alone.
The highest ROI sits at the intersection of anabolic signaling, sebaceous regulation, dermal collagen synthesis, and subcutaneous adipose redistribution. Compounds that modulate multiple pathways—selective androgen receptor modulators combined with growth hormone secretagogues, for example—consistently outperform single-target interventions. The looksmaxxing tier list below prioritizes protocols where 12 weeks of disciplined execution produces changes visible in standard photography under consistent lighting.
Mechanism
S-tier looksmaxxing interventions operate through four primary pathways: activation of androgen receptors in craniofacial skeletal muscle and dermal fibroblasts, stimulation of IGF-1-mediated protein synthesis and chondrocyte proliferation, inhibition of aromatase to preserve free testosterone and prevent adipose deposition in gynecomastoid and submental patterns, and upregulation of procollagen type I and III via TGF-β signaling in facial dermis.
Testosterone and its derivatives bind cytosolic androgen receptors in masseter, temporalis, and periorbital musculature, inducing hypertrophy that enhances jawline definition and brow ridge prominence. Simultaneously, AR activation in sebocytes increases sebum production and pore diameter—a negative aesthetic outcome that necessitates concurrent 5α-reductase inhibition in skin tissue. The dissociation between muscle AR activation (desirable) and sebaceous AR activation (undesirable) is why topical anti-androgens applied to facial skin can coexist with systemic anabolic protocols.
Growth hormone secretagogues—MK-677 (ibutamoren) at 15-25 mg daily or CJC-1295 without DAC at 100 mcg three times weekly—elevate serum IGF-1 into the 300-400 ng/mL range. IGF-1 promotes chondrocyte proliferation at the nasal septum and auricular cartilage, increases type II collagen deposition, and drives dermal thickness via fibroblast activation. The cosmetic result is improved skin turgor, reduced nasolabial fold depth, and subtle increases in soft tissue fullness. These effects require 16-20 weeks of sustained elevation; IGF-1 below 250 ng/mL produces negligible cosmetic benefit.
Aromatase inhibition prevents conversion of testosterone to estradiol, preserving androgenic signaling and preventing estrogen-mediated subcutaneous adipose accumulation in the lower face, submental region, and chest. Exemestane at 12.5 mg twice weekly or anastrozole at 0.25-0.5 mg twice weekly maintains estradiol in the 20-30 pg/mL range during supraphysiologic androgen protocols. Estradiol below 15 pg/mL degrades lipid panels and joint integrity; above 40 pg/mL negates the aesthetic advantage of elevated androgens.
Dermal remodeling via retinoids—tretinoin 0.05-0.1% nightly or oral isotretinoin 20-40 mg daily—upregulates TGF-β, increasing procollagen synthesis and epidermal turnover. This reduces photodamage, tightens skin texture, and minimizes pore diameter. Isotretinoin also ablates sebaceous gland function, eliminating acne and reducing pore visibility independent of androgen levels. The cosmetic benefit is proportional to cumulative dose: 120-150 mg/kg total isotretinoin produces durable sebaceous suppression for 24-36 months.
Protocol
S-Tier: Testosterone Base + GH Secretagogue + Aromatase Inhibitor
Testosterone enanthate 150-250 mg weekly, split into two subcutaneous injections of 75-125 mg every 3.5 days. This maintains trough levels between 800-1200 ng/dL, saturating androgen receptors in craniofacial muscle without requiring aggressive estrogen management. Pair with MK-677 25 mg taken nightly or CJC-1295 100 mcg three times weekly to elevate IGF-1 above 300 ng/mL. Add exemestane 12.5 mg every 3.5 days or anastrozole 0.5 mg every 3.5 days, titrated to keep estradiol between 20-30 pg/mL at week-6 bloodwork.
Visible changes emerge at week 8-10: increased masseter and temporalis bulk, reduced submental adipose, enhanced skin thickness. Duration: 16-24 weeks for peak effect. Post-cycle, maintain gains with 100-150 mg testosterone weekly long-term or accept 30-40% regression over 12 weeks as endogenous production normalizes.
A-Tier: Oral Isotretinoin + Topical Tretinoin
Isotretinoin 40 mg daily (for a 90 kg individual, 0.44 mg/kg/day) for 20-24 weeks to achieve cumulative dose of 120-150 mg/kg. Apply tretinoin 0.1% cream nightly to face, starting three times weekly for four weeks to build tolerance, then advancing to nightly application. This combination eliminates sebaceous output, erases active acne, tightens skin texture, and fades hyperpigmentation. Expect complete sebaceous suppression by week 8-12 of isotretinoin; skin texture improvement from tretinoin becomes visible at week 16-20.
Mandatory monitoring: fasting lipid panel at baseline, week 4, week 8, then every 8 weeks. Triglycerides above 400 mg/dL require dose reduction or fenofibrate 145 mg daily. ALT/AST above 2.5× upper limit requires cessation. Pair with omega-3 ethyl esters 4 g daily to blunt triglyceride elevation.
A-Tier: Selective Androgen Receptor Modulator Monotherapy
RAD-140 (testolone) 10 mg daily or LGD-4033 (ligandrol) 10 mg daily for 8-12 weeks. Both demonstrate preferential AR activation in skeletal muscle versus prostate and sebaceous tissue, though this selectivity is relative, not absolute. Expect 2-4 kg lean mass gain concentrated in androgen-dense musculature (jaw, traps, delts). Sebaceous activation occurs in 40-60% of users above 10 mg daily; if acne emerges, add topical clascoterone 1% twice daily to facial skin or reduce dose to 5 mg daily.
Post-cycle: 4 weeks of tamoxifen 10 mg daily or enclomiphene 12.5 mg daily if week-8 total testosterone drops below 300 ng/dL. No PCT necessary if total testosterone remains above 400 ng/dL at week 8.
B-Tier: Minoxidil + Microneedling for Facial Hair Density
Minoxidil 5% solution applied twice daily to beard region, combined with 1.5 mm microneedling once weekly. Minoxidil sulfotransferase in dermal papilla cells converts minoxidil to its active sulfate form, prolonging anagen phase. Microneedling induces controlled dermal injury, releasing platelet-derived growth factor and vascular endothelial growth factor, which recruit stem cells to follicles. Visible density increase requires 24-32 weeks; response rate is 60-70%. Cease microneedling 48 hours before and after minoxidil application to avoid systemic absorption and reflex tachycardia.
Monitoring
Baseline bloodwork before any looksmaxxing tier list protocol: total testosterone, free testosterone, estradiol (sensitive LC-MS/MS), IGF-1, lipid panel (total cholesterol, LDL, HDL, triglycerides), comprehensive metabolic panel (ALT, AST, creatinine, eGFR), CBC with differential, TSH, free T3. Repeat at week 4-6, then every 8-12 weeks during active intervention.
Testosterone protocols: Target trough total testosterone 800-1200 ng/dL, free testosterone 150-250 pg/mL, estradiol 20-30 pg/mL. Hematocrit above 52% requires phlebotomy (donate 450 mL whole blood) or dose reduction. Hemoglobin above 18 g/dL is mandatory cessation threshold. Monitor blood pressure every two weeks; sustained readings above 140/90 mmHg require addition of telmisartan 20-40 mg daily or nebivolol 5 mg daily.
GH secretagogue protocols: Target IGF-1 between 300-400 ng/mL. Fasting glucose should remain below 100 mg/dL; MK-677 induces insulin resistance in 30% of users, manifesting as fasting glucose 105-115 mg/dL. If fasting glucose exceeds 105 mg/dL, add metformin 500 mg twice daily or berberine 500 mg three times daily. HbA1c above 5.7% requires dose reduction or cessation. Monitor fasting glucose weekly for the first month, then monthly.
Isotretinoin protocols: Triglycerides are the primary risk. Baseline above 200 mg/dL contraindicates isotretinoin until corrected with diet or fenofibrate. On-treatment triglycerides above 400 mg/dL require immediate dose reduction by 50%. Recheck lipids two weeks after any dose adjustment. ALT or AST above 100 U/L (roughly 2.5× upper limit) is a stop signal; recheck in four weeks off-drug, and if normalized, resume at 50% dose. Monthly pregnancy tests for females of childbearing potential are non-negotiable.
Subjective monitoring: photograph face in identical lighting (direct overhead, neutral expression) every two weeks. Track jawline definition, submental contour, nasolabial fold depth, pore size, and overall skin texture. Quantify changes by overlaying images in photo editing software and measuring angles or distances. Perceived aesthetic improvement without photographic evidence is often lighting or confirmation bias.
Risks and Mitigation
Sebaceous hyperactivation and acne: Occurs with supraphysiologic androgens or SARMs in genetically susceptible individuals. Mitigation: isotretinoin 20 mg daily eliminates sebaceous output entirely; topical clascoterone 1% twice daily to face antagonizes AR locally without systemic effects; reduce androgen dose by 30-40% if neither option is acceptable.
Estradiol excess (gynecomastia, submental fat, water retention): Aromatase activity increases proportionally with testosterone dose and body fat percentage. Mitigation: anastrozole 0.5 mg or exemestane 12.5 mg every 3.5 days, titrated to estradiol 20-30 pg/mL. If gynecomastia tissue develops, add raloxifene 60 mg daily for 12-16 weeks to induce regression; surgical excision is definitive if pharmacologic reversal fails.
Polycythemia (hematocrit >52%, hemoglobin >18 g/dL): Testosterone stimulates erythropoiesis. Mitigation: donate whole blood every 8-12 weeks; switch from intramuscular to subcutaneous injection (reduces peak levels and erythropoietic drive); reduce testosterone dose by 20-30%. Aspirin 81 mg daily reduces thrombotic risk if phlebotomy alone is insufficient.
Hypertriglyceridemia (>400 mg/dL) on isotretinoin: Inhibition of lipoprotein lipase and hepatic VLDL clearance. Mitigation: omega-3 ethyl esters 4 g daily reduces triglycerides 20-30%; fenofibrate 145 mg daily if omega-3 is inadequate; reduce isotretinoin dose by 50%; eliminate simple carbohydrates and alcohol entirely.
Insulin resistance and fasting hyperglycemia on MK-677: GH elevation impairs insulin signaling. Mitigation: metformin 500-1000 mg twice daily restores insulin sensitivity; berberine 500 mg three times daily is non-prescription alternative; reduce MK-677 dose to 12.5 mg daily or switch to CJC-1295/ipamorelin which produce pulsatile rather than sustained GH elevation.
Comparisons
Testosterone 200 mg/week vs. RAD-140 10 mg/day: Testosterone produces greater muscle hypertrophy (4-6 kg lean mass over 12 weeks vs. 2-4 kg), more pronounced facial musculature changes, and superior strength gains. RAD-140 avoids testicular suppression in 40% of users at 10 mg daily and produces less sebaceous activation in most individuals. Testosterone requires aromatase inhibitor co-administration and post-cycle PCT or indefinite replacement; RAD-140 requires PCT in 60% of users. For pure aesthetic ROI, testosterone wins; for users seeking to avoid exogenous hormone replacement, RAD-140 is the compromise.
Oral isotretinoin vs. topical tretinoin monotherapy: Isotretinoin produces complete sebaceous ablation, eliminating acne and minimizing pore size, but carries significant lipid and teratogenic risk. Tretinoin improves skin texture and stimulates collagen synthesis without systemic risk, but does not suppress sebaceous output; active acne persists in most users. Combining both is synergistic: isotretinoin handles sebaceous pathology, tretinoin handles dermal remodeling. For users with severe acne or large pores, isotretinoin is non-negotiable; for users with clear skin seeking texture improvement, tretinoin alone suffices.
MK-677 25 mg/day vs. CJC-1295 + ipamorelin: MK-677 produces sustained GH and IGF-1 elevation with single daily dosing, costs $60-90 monthly, but induces insulin resistance and water retention in 30-40% of users. CJC-1295 + ipamorelin produces pulsatile GH release mimicking endogenous patterns, avoids insulin resistance, but requires three injections weekly and costs $150-200 monthly. For users with normal fasting glucose, MK-677 offers superior convenience; for users with prediabetes or strong insulin resistance family history, peptide combination is safer.
Common Mistakes
Initiating high-dose androgens without establishing AI dose: Users begin testosterone 400-500 mg weekly without concurrent aromatase inhibitor, experience rapid estradiol surge, develop gynecomastia tissue within 4-6 weeks, then add AI or SERM reactively. Correct approach: start AI simultaneously with first testosterone injection, obtain week-4 bloodwork, and titrate AI dose to estradiol 20-30 pg/mL before increasing testosterone further.
Stopping isotretinoin prematurely due to transient lipid elevation: Triglycerides spike to 250-350 mg/dL at week 4-8, user panics and discontinues. Correct approach: add omega-3 4 g daily at isotretinoin initiation, recheck lipids at week 8, add fenofibrate if triglycerides remain above 300 mg/dL, continue isotretinoin to cumulative target dose unless triglycerides exceed 400 mg/dL or ALT exceeds 100 U/L.
Neglecting sebaceous management during androgen protocols: Users run testosterone or SARMs, experience cystic acne at week 6-10, discontinue androgens, and lose aesthetic gains. Correct approach: initiate isotretinoin 20-40 mg daily simultaneously with androgen protocol, or apply topical clascoterone 1% twice daily to face prophylactically. Sebaceous hyperactivation is predictable and entirely preventable.
Chasing high IGF-1 without monitoring glucose: Users dose MK-677 at 25-50 mg daily, achieve IGF-1 above 400 ng/mL, ignore rising fasting glucose, develop prediabetes (HbA1c 5.8-6.2%) after 6-12 months. Correct approach: monitor fasting glucose every two weeks for first eight weeks on GH secretagogue, add metformin at first sign of impaired fasting glucose (>100 mg/dL), reduce dose if fasting glucose exceeds 110 mg/dL despite metformin.
Inconsistent photographic documentation: Users take progress photos in different lighting, different angles, different facial expressions, then cannot objectively assess change. Correct approach: standardize lighting (direct overhead or ring light), neutral expression, identical camera distance, same time of day. Take photos every 14 days, compile into grid, and overlay in software to measure angles and distances.
Bottom Line
- S-tier ROI: Testosterone enanthate 150-250 mg weekly + MK-677 25 mg daily + exemestane 12.5 mg twice weekly produces visible facial musculature and skin quality changes within 8-12 weeks.
- A-tier standalone: Isotretinoin 40 mg daily for 20-24 weeks eliminates sebaceous output and acne permanently; tretinoin 0.1% nightly improves dermal thickness and texture over 16-20 weeks.
- Monitor aggressively: Bloodwork at weeks 0, 4-6, then every 8-12 weeks for testosterone, estradiol, IGF-1, lipids, liver enzymes, CBC. Adjust doses based on markers, not subjective feel.
- Sebaceous control is non-negotiable: Isotretinoin 20-40 mg daily or topical clascoterone 1% prevents androgen-induced acne; address prophylactically, not reactively.
- Photographic documentation beats perception: Standardized lighting and angles every 14 days, overlaid in editing software, quantifies changes that subjective assessment misses.